Now, considerable effort is focused on how to best leverage immune checkpoint therapy for patients with resectable early-stage NSCLC and prevent post-operative tumor recurrence1, using adjuvant2 or neoadjuvant3 approaches targeting the PD-(L)1 axis. The gene discussed is CD274; the disease is neoplasm.